Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma

被引：0
|
作者：
Alice Indini
Lorenza Di Guardo
Carolina Cimminiello
Michele Prisciandaro
Giovanni Randon
Filippo De Braud
Michele Del Vecchio
机构：
[1] Fondazione IRCCS Istituto Nazionale dei Tumori di Milano,Melanoma Medical Oncology Unit, Department of Medical Oncology and Hematology
[2] Fondazione IRCCS Istituto Nazionale dei Tumori di Milano,Department of Medical Oncology and Hematology
[3] Fondazione IRCCS Istituto Nazionale dei Tumori di Milano,Università degli studi di Milano
来源：
Journal of Cancer Research and Clinical Oncology | 2019年 / 145卷
关键词：
Melanoma; Immunotherapy; Anti-PD1; IrAEs; Vitiligo; Toxicity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：511 / 521
页数：10
相关论文
共 50 条
  • [21] Exploring the clinical significance of specific immune-related adverse events in melanoma patients undergoing immune checkpoint inhibitor therapy
    Asher, Nethanel
    Bar-Hai, Neta
    Ben-Betzalel, Guy
    Stoff, Ronen
    Grynberg, Shirly
    Schachter, Jacob
    Frommer-Shapira, Ronnie
    MELANOMA RESEARCH, 2024, 34 (05) : 439 - 449
  • [22] Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy
    Finazzi, T.
    Rordorf, T.
    Ikenberg, K.
    Huber, G. F.
    Guckenberger, M.
    Schueler, H. I. Garcia
    BMC CANCER, 2018, 18
  • [23] Immune-related adverse events are associated with therapeutic efficacy of immunotherapy in patients with melanoma brain metastases
    Huo, Cecilia W.
    Gunadasa, Indika
    Gkolia, Panagiota
    Shackleton, Mark
    Hunn, Martin
    MELANOMA RESEARCH, 2023, 33 (01) : 58 - 65
  • [24] Effect of excess weight and immune-related adverse events on the efficacy of cancer immunotherapy with anti-PD-1 antibodies
    Rogado, Jacobo
    Romero-Laorden, Nuria
    Miguel Sanchez-Torres, Jose
    Maria Ramos-Levi, Ana
    Pacheco-Barcia, Vilma
    Isabel Ballesteros, Ana
    Arranz, Reyes
    Lorenzo, Alicia
    Gullon, Pedro
    Garrido, Ana
    Serra Lopez-Matencio, Jose Maria
    Donnay, Olga
    Adrados, Magdalena
    Costas, Pablo
    Aspa, Javier
    Alfranca, Arantzazu
    Mondejar, Rebeca
    Colomer, Ramon
    ONCOIMMUNOLOGY, 2020, 9 (01):
  • [25] Thyroid Immune-Related Adverse Events in Patients with Cancer Treated with anti-PD1/anti-CTLA4 Immune Checkpoint Inhibitor Combination: Clinical Course and Outcomes
    Lui, David Tak Wai
    Lee, Chi Ho
    Tang, Vikki
    Fong, Carol Ho Yi
    Lee, Alan Chun Hong
    Chiu, Joanne Wing Yan
    Leung, Roland Ching Yu
    Kwok, Gerry Gin Wai
    Li, Bryan Cho Wing
    Cheung, Tan To
    Woo, Yu Cho
    Lam, Karen Siu Ling
    Yau, Thomas
    ENDOCRINE PRACTICE, 2021, 27 (09) : 886 - 893
  • [26] Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors
    Cook, Sarah
    Samuel, Vanessa
    Meyers, Daniel E.
    Stukalin, Igor
    Litt, Ishjot
    Sangha, Randeep
    Morris, Don G.
    Heng, Daniel Y. C.
    Pabani, Aliyah
    Dean, Michelle
    Navani, Vishal
    JAMA NETWORK OPEN, 2024, 7 (01) : E2352302
  • [27] Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy
    Amato, Carol M.
    Hintzsche, Jennifer D.
    Wells, Keith
    Applegate, Allison
    Gorden, Nicholas T.
    Vorwald, Victoria M.
    Tobin, Richard P.
    Nassar, Kelsey
    Shellman, Yiqun G.
    Kim, Jihye
    Medina, Theresa M.
    Rioth, Matthew
    Lewis, Karl D.
    McCarter, Martin D.
    Gonzalez, Rene
    Tan, Aik-Choon
    Robinson, William A.
    CANCERS, 2020, 12 (07) : 1 - 15
  • [28] Immune-related adverse events in a patient with eosinophilic enteritis treated with immune checkpoint inhibitors (anti-PD-1)
    Cybulska-Stopa, Bozena
    Kaminska-Winciorek, Grazyna
    Dyduch, Grzegorz
    MELANOMA RESEARCH, 2020, 30 (06) : 619 - 624
  • [29] The prognostic impact of immune-related adverse events during anti-PD1 treatment in melanoma and non-small-cell lung cancer: a real-life retrospective study
    Dupont, R.
    Berard, E.
    Puisset, F.
    Comont, T.
    Delord, J-P
    Guimbaud, R.
    Meyer, N.
    Mazieres, J.
    Alric, L.
    ONCOIMMUNOLOGY, 2020, 9 (01):
  • [30] Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients
    Rogado, J.
    Sanchez-Torres, J. M.
    Romero-Laorden, N.
    Ballesteros, A., I
    Pacheco-Barcia, V
    Ramos-Levi, A.
    Arranz, R.
    Lorenzo, A.
    Gullon, P.
    Donnay, O.
    Adrados, M.
    Costas, P.
    Aspa, J.
    Alfranca, A.
    Mondejar, R.
    Colomer, R.
    EUROPEAN JOURNAL OF CANCER, 2019, 109 : 21 - 27
12345